natgillin/translations-raw huggingface dataset:
c.218 C &gt; T
c.216 G &gt; A
c.227 T &gt; C
c.218 C &gt; T
c.227 T &gt; G
c.233 C &gt; G
c.233 C &gt; G
c.235 G &gt; T
c.235 G &gt; T
c.241 T &gt; C
c.241 T &gt; C
c.242 G &gt; A
c.242 G &gt; A
c.242 G &gt; C
c.242 G &gt; C
c.243 G &gt; T
c.243 G &gt; T
c.244 A &gt; T
c.244 A &gt; T
c.256 T &gt; G
c.247 G &gt; A
c.227 T &gt; C
c.256 T &gt; C
c.257 A &gt; G
c.256 T &gt; G
c.256 T &gt; C
c.257 A &gt; G
c.258 T &gt; G
c.258 T &gt; G
c.262 T &gt; G
c.262 T &gt; G
c.266 T &gt; C
c.266 T &gt; C
c.266 T &gt; G
c.334 C &gt; A
c.334 C &gt; T
c.334 C &gt; T
c.320 A &gt; T
c.338 T &gt; C
c.334 C &gt; A
c.350 T &gt; G
c.338 T &gt; C
c.493 G &gt; T
c.491 T &gt; G
c.494 A &gt; T
c.493 G &gt; T
c.500 T &gt; A
c.494 A &gt; T
c.500 T &gt; C
c.500 T &gt; A
c.547 G &gt; A (putative splicing site )
c.547 G &gt; A (pretpostavljeno mjesto prekrajanja)
c.611 G &gt; A or 612G &gt; A
c.611 G &gt; A ili 612G &gt; A
c.62 T &gt; C
c.61C &gt; T
c.62 T &gt; G
c.62 T &gt; C
c.680 G &gt; C
c.680 G &gt; A
c.688 G &gt; A
c.680 G &gt; C
c.691 G &gt; A
c.688 G &gt; A
c.692 A &gt; G
c.691 G &gt; A
c.734 G &gt; A or 735G &gt; A
c.734 G &gt; A ili 735G &gt; A
c.749 A &gt; C
c.747 C &gt; G
c.758 T &gt; C
c.749 A &gt; C
c.758 T &gt; G
c.758 T &gt; C
c.760-762del GTT
c.758 T &gt; G
c.801 G &gt; A (putative splicing site )
c.801 G &gt; A (pretpostavljeno mjesto prekrajanja)
c.823 C &gt; T
c.821 G &gt; T
c.826 A &gt; G
c.823 C &gt; T
c.830 G &gt; A
c.826 A &gt; G
c.835 C &gt; A
c.830 G &gt; A
c.860 G &gt; A or 861G &gt; A
c.860 G &gt; A ili 861G &gt; A
c.908 T &gt; A
c.902 G &gt; T
c.911 G &gt; A
c.908 T &gt; A
c.911 G &gt; C
c.911 G &gt; A
c.988 C &gt; T
c.983 G &gt; T
c.997 C &gt; T
c.988 C &gt; T
c.998 A &gt; G
c.997 C &gt; T
c.[644 A &gt; G; 811 G &gt; A; 937 G &gt; T]
c.[644 A &gt; G; 811 G &gt; A; 937
c: subjects &lt; 75 kg received 100 µg/week peginterferon alfa-2b and subjects ≥ 75 kg received 150 µg/week peginterferon alfa-2b . d: Ribavirin dosing was 800 mg for patients &lt; 60 kg, 1,000 mg for patients 60-75 kg, and 1,200 mg for patients &gt; 75 kg.
c: ispitanici teški &lt; 75 kg primali su 100 μg lijeka peginterferon alfa 2-b na tjedan, a ispitanici teški ≥ 75 kg primali su 150 μg lijeka peginterferon alfa-2b na tjedan. d: doza ribavirina iznosila je 800 mg za bolesnike teške &lt; 60 kg, 1000 mg za bolesnike teške 60-75 kg, te 1200 mg za bolesnike teže od 75 kg.
c: subjects &lt; 75 kg received 100 µg/week peginterferon alfa-2b and subjects ≥ 75 kg received 150 µg/week peginterferon alfa-2b . d: Ribavirin dosing was 800 mg for patients &lt; 60 kg, 1,000 mg for patients 60-75 kg, and 1,200 mg for patients &gt; 75 kg.
c: ispitanici teški &lt; 75 kg primali su 100 μg lijeka peginterferon alfa-2b na tjedan, a ispitanici teški ≥ 75 kg primali su 150 μg lijeka peginterferon na tjedan. d: doza lijeka ribavirin iznosila je 800 mg za bolesnike teške &lt; 60 kg, 1000 mg za bolesnike teške 60-75 kg, te 1200 mg za bolesnike teže od 75 kg.
c: subjects &lt; 75 kg received 100 µg/week peginterferon alfa-2b and subjects ≥ 75 kg received 150 µg/week peginterferon alfa-2b . d: Ribavirin dosing was 800 mg for patients &lt; 60 kg, 1,000 mg for patients 60-75 kg, and 1,200 mg for patients &gt; 75 kg.
c: ispitanici teški &lt; 75 kg primali su 100 μg lijeka peginterferon alfa-2b na tjedan, a ispitanici teški ≥ 75 kg primali su 150 μg peginterferon alfa-2b na tjedan. d: doza lijeka Ribavirin iznosila je 800 mg za bolesnike teške &lt; 60 kg, 1000 mg za bolesnike teške 60-75 kg, te 1200 mg za bolesnike teže od 75 kg.
c: subjects &lt; 75 kg received 100 µg/week pegylated interferon alfa-2b and subjects ≥ 75 kg received 150 µg/week pegylated interferon alfa-2b. d: ribavirin dosing was 800 mg for patients &lt; 60 kg, 1,000 mg for patients 60-75 kg, and 1,200 mg for patients &gt; 75 kg.
c: ispitanici teški &lt; 75 kg primali su 100 μg pegiliranog interferona alfa-2b na tjedan, a ispitanici teški ≥ 75 kg primali su 150 μg pegiliranog interferona alfa-2b na tjedan. d: doza ribavirina iznosila je 800 mg za bolesnike teške &lt; 60 kg, 1000 mg za bolesnike teške 60-75 kg, te 1200 mg za bolesnike ≥ 75 kg.
CA was defined as the proportion of all subjects treated who did not smoke (not even a puff of a cigarette) from Week 9 through Week 52 and did not have an exhaled CO measurement of &gt; 10 ppm.
CA je definirana kao stopa svih liječenih ispitanika koji nisu pušili (čak niti jedan dim cigarete) između 9. i 52. tjedna i u kojih izmjerena količina CO u izdisaju nije bila &gt; 10 ppm.
Cabazitaxel is extensively metabolised in the liver ( &gt; 95%), mainly by the CYP3A isoenzyme (80% to 90%).
Kabazitaksel se većinom metabolizira u jetri ( &gt; 95%), uglavnom pomoću izoenzima CYP3A (80% do 90%).
Cabozantinib is a substrate for CYP3A4 metabolism in vitro, as a neutralizing antibody to CYP3A4 inhibited formation of metabolite XL184 N-oxide by &gt; 80% in a NADPH-catalyzed human liver microsomal (HLM) incubation; in contrast, neutralizing antibodies to CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2D6 and CYP2E1 had no effect on cabozantinib metabolite formation.
Kabozantinib je supstrat za metabolizam CYP3A4 in vitro; kao neutralizirajuće antitijelo CXP3A4 inhibirao je formaciju metabolita XL184 N-oksida za &gt; 80% u mikrosomalnoj inkubaciji ljudske jetre (HLM) kataliziranoj NADP-om; za razliku od toga, neutralizirajuća antitijela CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2D6 i CYP2E1 nisu imala učinak na formaciju metabolita kabozantiniba.
Cabozantinib is a substrate for CYP3A4 metabolism in vitro, as a neutralizing antibody to CYP3A4 inhibited formation of metabolite XL184 N-oxide by &gt; 80% in a NADPH-catalyzed human liver microsomal (HLM) incubation; in contrast, neutralizing antibodies to CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2D6 and CYP2E1 had no effect on cabozantinib metabolite formation.
Kabozantinib je supstrat za metabolizam putem CYP3A4 in vitro; budući da je neutralizirajuće protutijelo na CYP3A4 inhibiralo stvaranje metabolita XL184 N-oksida za &gt; 80 % pri inkubaciji s mikrosomima ljudske jetre (HLM) kataliziranoj NADPH-om; za razliku od toga, neutralizirajuća protutijela na CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2D6 i CYP2E1 nisu imala učinak na stvaranje metabolita kabozantiniba.
Canagliflozin has not been studied in severe renal impairment (eGFR &lt; 30 mL/min/1.73 m2 or CrCl &lt; 30 mL/min) or ESRD.
Kanagliflozin nije ispitan pri teškom oštećenju bubrega (eGFR &lt; 30 mL/min/1,73 m2 ili CrCl &lt; 30 mL/min) ili u završnom stadiju bubrežne bolesti.
Candida albicans: S ≤0.06 mg/L, R &gt; 0.06 mg/L
Candida albicans: S ≤0,06 mg/l, R &gt; 0,06 mg/l
Candida parapsilosis: S ≤0.06 mg/L, R &gt; 0.06 mg/L
Candida parapsilosis: S ≤0,06 mg/l, R &gt; 0,06 mg/l
Candida tropicalis: S ≤0.06 mg/L, R &gt; 0.06 mg/L
Candida tropicalis: S ≤0,06 mg/l, R &gt; 0,06 mg/l
Capillary leak syndrome was a very common adverse reaction (45 % of patients) that occurred more frequently when Unituxin was co-administered with IL-2; it was severe ( &gt; Grade 3) in 14% of patients.
Sindrom kapilarnog curenja je bio vrlo česta nuspojava (u 45% bolesnika) koja se pojavljivala češće kada se Unituxin primjenjivao zajedno s IL-2; bila je teška ( &gt; 3. stupnja) u 14% bolesnika.
Capillary Leak Syndrome, which can be life-threatening if treatment is delayed, has been reported as uncommon (≥ 1/1,000 to &lt; 1/100) in cancer patients undergoing chemotherapy following administration of granulocyte colony-stimulating factors; see section 4.4 and section “Description of selected adverse reactions” below.
Sindrom povećane propusnosti kapilara, koji može biti životno ugrožavajući ukoliko se ne počne liječiti na vrijeme, prijavljen je manje često (≥ 1/1000 do &lt; 1/100) u bolesnika s rakom koji su na kemoterapiji nakon primjene faktora stimulacije rasta granulocita; vidjeti dio 4.4 i dio „Opis odabranih nuspojava“ ispod.
Capillary leak syndrome, which can be life-threatening if treatment is delayed, has been reported uncommonly (≥ 1/1000 to &lt; 1/100) in cancer patients undergoing chemotherapy and healthy donors undergoing peripheral blood progenitor cell mobilisation following administration of G-CSFs; see section 4.4 and subsection “Description of selected adverse reactions” of section 4.8.
Sindrom povećane propusnosti kapilara, koji može biti životno ugrožavajući ukoliko se ne počne liječiti na vrijeme, prijavljen je manje često (≥ 1/1000 i &lt; 1/100) u bolesnika s rakom koji su na kemoterapiji i zdravih darivatelja u kojih se provodila mobilizacija progenitorskih stanica periferne krvi nakon primjene G-CSF-a; vidjeti dio 4.4 i odjeljak „Opis odabranih nuspojava“ dijela 4.8.
Capillary leak syndrome, which can be life-threatening if treatment is delayed, has been reported uncommonly (≥ 1/1000 to &lt; 1/100) in cancer patients undergoing chemotherapy and healthy donors undergoing peripheral blood progenitor cell mobilisation following administration of granulocyte colony- stimulating factors; see section 4.4 and subsection C of section 4.8.
Sindrom povećane propusnosti kapilara, koji može ugrožavati život ako se ne počne liječiti na vrijeme, prijavljen je manje često (≥ 1/1000 do &lt; 1/100) u bolesnika s rakom koji su na kemoterapiji i zdravih davatelja u kojih se provodi mobilizacija krvotvornih matičnih stanica periferne krvi nakon primjene faktora stimulacije granulocitnih kolonija (vidjeti dio 4.4 i poddio C dijela 4.8.
Capillary leak syndrome, which can be life-threatening if treatment is delayed, has been reported uncommonly (≥ 1/1000 to &lt; 1/100) in cancer patients undergoing chemotherapy and healthy donors undergoing peripheral blood progenitor cell mobilisation following administration of granulocyte colony-stimulating factors (see section 4.4 and section 4.8).
Stanje povećane kapilarne propusnosti, koje u slučaju nepravodobnog liječenja može biti opasno po život, javlja se manje često (≥ 1/1000 do &lt; 1/100) u bolesnika na kemoterapiji i u zdravih donora koji su mobilizirali krvotvorne matične stanice iz periferne krvi nakon primjene čimbenika poticanja granulocitnih kolonija (vidjeti odjeljak 4.4 i odjeljak 4.8).
Capillary Leak Syndrome, which can be life-threatening if treatment is delayed, has been reported uncommonly (≥ 1/1000 to &lt; 1/100) in cancer patients undergoing chemotherapy and healthy donors undergoing peripheral blood progenitor cell mobilisation following administration of granulocyte colony-stimulating factors; see below and section 4.4.
Sindrom povećane propusnosti kapilara, koji može ugrožavati život ako se ne počne liječiti na vrijeme, prijavljen je manje često (≥ 1/1000 do &lt; 1/100) u bolesnika s rakom koji su na kemoterapiji i zdravih davatelja u kojih se provodi mobilizacija progenitorskih stanica iz periferne krvi nakon primjene faktora stimulacije granulocitnih kolonija; vidjeti niže i dio 4.4.
Capillary leak syndrome, which can be life-threatening if treatment is delayed, has been reported uncommonly (≥ 1/1000 to &lt; 1/100) in cancer patients undergoing chemotherapy and healthy donors undergoing peripheral blood progenitor cell mobilization following administration of granulocyte colony-stimulating factors (see section 4.4 and section 4.8).
Stanje povećane kapilarne propusnosti, koje u slučaju nepravodobnog liječenja može biti opasno po život, javlja se manje često (≥ 1/1000 do &lt; 1/100) u bolesnika na kemoterapiji i u zdravih donora koji su mobilizirali krvotvorne matične stanice iz periferne krvi nakon primjene čimbenika poticanja granulocitnih kolonija (vidjeti odjeljak 4.4 i odjeljak 4.8).
Cardiac arrhythmias particularly tachycardia (0.8% vs &lt; 0.1%) and palpitations (1.5% vs 0.8%) have been reported in lixisenatide patients compared to placebo treated patients.
U bolesnika liječenih liksisenatidom u usporedbi s bolesnicima koji su primali placebo prijavljene su srčane aritmije, osobito tahikardija (0,8% naspram &lt; 0,1%) i palpitacije (1,5% naspram 0,8%).
Cardiac events were reported as serious adverse events (including atrial fibrillation, myocardial infarction, left ventricular failure, myocardial ischaemia) in 3% of patients treated with MabThera compared to &lt; 1% on observation.
Srčani događaji su prijavljeni kao ozbiljne nuspojave (uključujući fibrilaciju atrija, infarkt miokarda, zatajenje lijeve klijetke i ishemiju miokarda) u 3% bolesnika liječenih lijekom MabThera u usporedbi s &lt; 1% bolesnika u opservacijskoj skupini.
Cardiac events were reported as serious adverse events (including atrial fibrillation, myocardial infarction, left ventricular failure, myocardial ischemia) in 3% of patients treated with MabThera compared to &lt; 1% on observation.
Srčani događaji su prijavljeni kao ozbiljne nuspojave (uključujući fibrilaciju atrija, infarkt miokarda, zatajenje lijeve klijetke i ishemiju miokarda) u 3% bolesnika liječenih lijekom MabThera u usporedbi s &lt; 1% bolesnika u opservacijskoj skupini.
Cardiac failure ( &lt; 1%) and decreased left ventricular ejection fraction have been reported in patients treated with lenvatinib (see section 4.8, Description of selected adverse reactions).
U bolesnika liječenih lenvatinibom zabilježeni su zatajenje srca ( &lt; 1%) i smanjena ejekcijska frakcija lijeve klijetke (vidjeti dio 4.8 Opis odabranih nuspojava).
Cardiac failure ( &lt; 1%) and decreased left ventricular ejection fraction have been reported in patients treated with lenvatinib (see section 4.8, Description of selected adverse reactions).
U bolesnika liječenih lenvatinibom zabilježeno je zatajenje srca ( &lt; 1%) i smanjena ejekcijska frakcija lijeve klijetke (vidjeti dio 4.8 Opis odabranih nuspojava).
Carriers of the SLCO1B1 gene c.521T &gt; C allele have lower OATP1B1 activity.
Nositelji alela c.521T &gt; C gena SLCO1B1 imaju nižu aktivnost OATP1B1.
Carton for 30 x 0.35 ml containers &amp; carton of 60 x 0.35 ml containers
Kutija s 30 spremnika x 0,35 ml i kutija sa 60 spremnika x 0,35 ml
CARTON OF &lt; 28 &gt; &lt; 30 &gt; &lt; 35 &gt; &lt; 50 &gt; &lt; 56 &gt; &lt; 70 &gt; &lt; 98 &gt; OLANZAPINE TEVA 10 mg ORODISPERSIBLE TABLETS
KUTIJA SA &lt; 28 &gt; &lt; 30 &gt; &lt; 35 &gt; &lt; 50 &gt; &lt; 56 &gt; &lt; 70 &gt; &lt; 98 &gt; OLANZAPIN TEVA 10 mg RASPADLJIVIH TABLETA ZA USTA
CARTON OF &lt; 28 &gt; &lt; 30 &gt; &lt; 35 &gt; &lt; 50 &gt; &lt; 56 &gt; &lt; 70 &gt; &lt; 98 &gt; OLANZAPINE TEVA 15 mg ORODISPERSIBLE TABLETS
KUTIJA SA &lt; 28 &gt; &lt; 30 &gt; &lt; 35 &gt; &lt; 50 &gt; &lt; 56 &gt; &lt; 70 &gt; &lt; 98 &gt; OLANZAPIN TEVA 15 mg RASPADLJIVIH TABLETA ZA USTA
CARTON OF &lt; 28 &gt; &lt; 30 &gt; &lt; 35 &gt; &lt; 50 &gt; &lt; 56 &gt; &lt; 70 &gt; &lt; 98 &gt; OLANZAPINE TEVA 5 mg ORODISPERSIBLE TABLETS
KUTIJA SA &lt; 28 &gt; &lt; 30 &gt; &lt; 35 &gt; &lt; 50 &gt; &lt; 56 &gt; &lt; 70 &gt; &lt; 98 &gt; OLANZAPIN TEVA 5 mg RASPADLJIVIH TABLETA ZA USTA
CARTON OF &lt; 28 &gt; &lt; 30 &gt; &lt; 35 &gt; &lt; 50 &gt; &lt; 56 &gt; &lt; 70 &gt; &lt; 98 &gt; OLANZAPINE TEVA 15 mg FILM-COATED TABLETS
KUTIJA SA &lt; 28 &gt; &lt; 30 &gt; &lt; 35 &gt; &lt; 50 &gt; &lt; 56 &gt; &lt; 70 &gt; &lt; 98 &gt; OLANZAPIN TEVA 15 mg FILMOM OBLOŽENIH TABLETA
CARTON OF &lt; 28 &gt; &lt; 30 &gt; &lt; 35 &gt; &lt; 56 &gt; &lt; 70 &gt; &lt; 98 &gt; OLANZAPINE TEVA 20 mg FILM-COATED TABLETS
KUTIJA SA &lt; 28 &gt; &lt; 30 &gt; &lt; 35 &gt; &lt; 56 &gt; &lt; 70 &gt; &lt; 98 &gt; OLANZAPIN TEVA 20 mg FILMOM OBLOŽENIH TABLETA
CARTON OF &lt; 28 &gt; &lt; 30 &gt; &lt; 35 &gt; &lt; 56 &gt; &lt; 70 &gt; &lt; 98 &gt; OLANZAPINE TEVA 20 mg ORODISPERSIBLE TABLETS
KUTIJA SA &lt; 28 &gt; &lt; 30 &gt; &lt; 35 &gt; &lt; 56 &gt; &lt; 70 &gt; &lt; 98 &gt; OLANZAPIN TEVA 20 mg RASPADLJIVIH TABLETA ZA USTA
CARTON OF &lt; 28 &gt; &lt; 30 &gt; &lt; 35 &gt; &lt; 56 &gt; &lt; 70 &gt; &lt; 98 &gt; OLANZAPINE TEVA 2.5 mg FILM-COATED TABLETS
KUTIJA SA &lt; 28 &gt; &lt; 30 &gt; &lt; 35 &gt; &lt; 56 &gt; &lt; 70 &gt; &lt; 98 &gt; OLANZAPIN TEVA 2,5 mg FILMOM OBLOŽENIH TABLETA
Cases ( &lt; 1%) of cholecystitis have been reported in CE/bazedoxifene clinical trials.
U kliničkim ispitivanjima s konjugiranim estrogenom/bazedoksifenom prijavljeni su slučajevi kolecistitisa ( &lt; 1%).
Cases of hepatic failure, including fatal cases, have been reported in &lt; 1% of subjects in clinical studies with Kyprolis.
Slučajevi zatajenja jetre, uključujući smrtne slučajeve, prijavljeni su u &lt; 1% ispitanika u kliničkim ispitivanjima lijeka Kyprolis.
Cases of hepatic failure, some with a fatal outcome, were observed in &lt; 1% of solid tumor patients treated with sunitinib.
Zabilježeni su slučajevi zatajivanja jetre, neki sa smrtnim ishodom, u &lt; 1% bolesnika sa solidnim tumorom liječenih sunitinibom.
Cases of interstitial nephritis with medullary calcification and cortical atrophy have been observed in patients with asymptomatic severe leucocyturia ( &gt; 100 cells/high power field).
U bolesnika s teškom asimptomatskom leukociturijom ( &gt; 100 stanica u vidnom polju mikroskopa pri velikom povećanju) primijećeni su slučajevi intersticijskog nefritisa s medularnom kalcifikacijom i kortikalnom atrofijom.
Cases of lactic acidosis, sometimes fatal, usually associated with severe hepatomegaly and hepatic steatosis, have been reported in &lt; 1% of patients taking stavudine in combination with other antiretrovirals (see section 4.4).
Slučajevi laktične acidoze, ponekad sa smrtnim ishodom, obično povezane s teškom hepatomegalijom i steatozom jetre, zabilježeni su u &lt; 1% bolesnika koji uzimaju stavudin u kombinaciji s drugim antiretrovirusnim lijekovima (vidjeti dio 4.4).
Cases of liver injury, including elevation of liver enzymes ( &gt; 10 times upper limit of normal), hepatitis and jaundice have been reported with toremifene.
Uz primjenu toremifena zabilježeni su slučajevi oštećenja jetre, uključujući povišenje jetrenih enzima ( &gt; 10 puta iznad gornje granice normale), hepatitis i žuticu.
Cases of liver injury, including severe elevations of liver enzymes ( &gt; 10 times upper limit of normal), hepatitis and jaundice have been reported with duloxetine (see section 4.8).
Kod primjene duloksetina prijavljeni su slučajevi oštećenja jetre, uključujući jako povišenje vrijednosti jetrenih enzima ( &gt; 10 puta iznad gornje granice normale), hepatitis i žuticu (vidjeti dio 4.8).
Cases of liver injury, including severe elevations of liver enzymes ( &gt; 10 times upper limit of normal), hepatitis and jaundice have been reported with duloxetine (see section 4.8).
Kod primjene duloksetina prijavljeni su slučajevi oštećenja jetre, uključujući velika povišenja jetrenih enzima ( &gt; 10 puta iznad gornje granice normale), hepatitis i žutica (vidjeti dio 4.8).
Cases of liver injury, including severe elevations of liver enzymes ( &gt; 10 times upper limit of normal), hepatitis and jaundice have been reported with duloxetine (see section 4.8).
Kod primjene duloksetina prijavljeni su slučajevi oštećenja jetre, uključujući velika povišenja jetrenih enzima ( &gt; 10 puta iznad gornje granice normale), hepatitis i žuticu (vidjeti dio 4.8).
Cases of symptomatic hypotension have been reported in patients treated with Entresto during clinical studies (see section 4.8), especially in patients ≥65 years old, patients with renal disease and patients with low SBP ( &lt; 112 mmHg).
Slučajevi simptomatske hipotenzije zabilježeni su u bolesnika liječenih Entrestom tijekom kliničkih ispitivanja (vidjeti dio 4.8), osobito u bolesnika u dobi od ≥65 godina, bolesnika s bolesti bubrega i bolesnika s niskim SKT-om ( &lt; 112 mmHg).
Cases of symptomatic hypotension have been reported in patients treated with Neparvis during clinical studies (see section 4.8), especially in patients ≥65 years old, patients with renal disease and patients with low SBP ( &lt; 112 mmHg).
Slučajevi simptomatske hipotenzije zabilježeni su u bolesnika liječenih Neparvisom tijekom kliničkih ispitivanja (vidjeti dio 4.8), osobito u bolesnika u dobi od ≥65 godina, bolesnika s bolesti bubrega i bolesnika s niskim SKT-om ( &lt; 112 mmHg).
Cats &lt; 2.5 kg
Mačke &lt; 2,5 kg
Caution is advised when administering Cubicin to patients who already have some degree of renal impairment (creatinine clearance &lt; 80 ml/min) before commencing therapy with Cubicin.
Savjetuje se oprez pri primjeni Cubicina u bolesnika s već prisutnim oštećenjem bubrega određenoga stupnja (klirens kreatinina &lt; 80 ml/min) prije početka terapije Cubicinom.
Caution is recommended in patients with haemoglobin &lt; 10 g/dl and appropriate measures should be taken as clinically indicated.
U bolesnika s vrijednošću hemoglobina &lt; 10 g/dl preporučuje se oprez te je potrebno poduzeti odgovarajuće mjere sukladno kliničkoj slici.
Caution is recommended in when administering Iclusig to patients with estimated creatinine clearance of &lt; 50 mL/min or end-stage renal disease (see section 4.2).
Preporučuje se oprez prilikom primjene lijeka Iclusig bolesnicima s klirensom kreatinina &lt; 50 ml/min ili bolesnicima u terminalnoj fazi bubrežnog zatajenja (vidjeti dio 4.2).
Caution is recommended when administering Iclusig to patients with estimated creatinine clearance of &lt; 50 mL/min, or end-stage renal disease.
Preporučuje se oprez prilikom primjene lijeka Iclusig bolesnicima s klirensom kreatinina &lt; 50 ml/min ili s terminalnom fazom bubrežnog zatajenja.
Caution is recommended when dosing patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) (see section 4.4 and 5.2).
Preporučuje se oprez pri doziranju u bolesnika s teškim bubrežnim oštećenjem (klirens kreatinina &lt; 30 ml/min) (vidjeti dijelove 4.4 i 5.2).
Caution is recommended when dosing patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) (see section 4.4 and 5.2).
Preporučuje se oprez pri doziranju u bolesnika s teškim bubrežnim oštećenjem (klirens kreatinina &lt; 30 ml/min) (vidjeti dijelove 4.4. i 5.2).
Caution is recommended when dosing patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) (see sections 4.2 and 5.2).
Preporučuje je oprez prilikom doziranja bolesnika s teškim oštećenjima bubrega (klirens kreatinina &lt; 30 ml/min) (vidjeti dijelove 4.2 i 5.2).
Caution is recommended when dosing patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) (see sections 4.2 and 5.2).
Preporučuje se oprez prilikom doziranja bolesnika s teškim oštećenjima bubrega (klirens kreatinina &lt; 30 ml/min) (vidjeti dijelove 4.2 i 5.2).
Caution should be exercised in patients for whom a canagliflozin-induced drop in blood pressure could pose a risk, such as patients with known cardiovascular disease, patients with an eGFR &lt; 60 mL/min/1.73 m2, patients on anti-hypertensive therapy with a history of hypotension, patients on diuretics, or elderly patients (≥ 65 years of age) (see sections 4.2 and 4.8).
Potreban je oprez u bolesnika kod kojih kanagliflozinom izazvano smanjenje krvnog tlaka može predstavljati rizik, poput bolesnika s poznatom kardiovaskularnom bolešću, bolesnika s eGFR &lt; 60 mL/min/1,73 m2, bolesnika na antihipertenzivnoj terapiji s anamnezom hipotenzije, bolesnika na diureticima ili u starijih bolesnika (≥ 65 godina starosti) (vidjeti dijelove 4.2 i 4.8).
Caution should be exercised in the administration of Dacogen to patients with severe renal impairment (Creatinine Clearance [CrCl] &lt; 30 ml/min) and these patients should be monitored closely (see section 4.2).
Kad se Dacogen primjenjuje u bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina [CrCl] &lt; 30 ml/min) potrebno je postupati s oprezom, a bolesnike pažljivo nadzirati (vidjeti dio 4.2).
Caution should be exercised when considering initiation of RoActemra treatment in patients with elevated ALT or AST &gt; 1.5 x ULN.
Potreban je oprez kad se razmatra liječenje lijekom RoActemra kod bolesnika s vrijednostima ALT-a ili AST-a &gt; 1,5 x iznad gornje granice normale.
Caution should be exercised when prescribing dalbavancin to patients with moderate or severe hepatic impairment (Child-Pugh B &amp; C) as no data are available to determine appropriate dosing (see sections 5.2).
Pri propisivanju dalbavancina bolesnicima s umjerenim ili teškim oštećenjem jetre (Child-Pugh B &amp; C) potreban je oprez, jer nema raspoloživih podataka za određivanje odgovarajućeg doziranja (vidjeti dio 5.2).